Author(s): Robert Perttilä, Modulight, Inc. (Finland); John Roque, The Univ. of Texas at Arlington (United States); Lasse Orsila, Modulight, Inc. (Finland), Tampere Univ. Hospital (Finland); Zoe Ylöniemi, Elias Kokko, Modulight, Inc. (Finland); Colin G. Cameron, Sherri A. McFarland, The Univ. of Texas at Arlington (United States); Petteri Uusimaa, Modulight, Inc. (Finland)
Digital Forum: On-demand now
Show Abstract +
Prodrug development for cancer treatment is urgently needed. One recent prodrug example, the light-activated TLD1433, has successfully begun phase II clinical trials for bladder cancer. Development of phototherapeutics, however, has a critical bottleneck since no high-throughput platform has been introduced, limiting development of phototherapeutics. This type of drug screening calls for an automated and scalable plate illuminator. We have developed the ML8500 illuminator to address this need, enabling flexible experimental design with systematic control over the light parameters (wavelength, irradiance, fluence) and multiplexing capability with fluorescence detection. Herein, we report characterization and early filtering of phototherapeutics with the ML8500.